MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Quadruple therapy shows 100 percent SVR for HCV patients

Back to infectious disease news Blogs list Cancer blog  


Subscribe To Infectious Disease News RSS Feed  RSS content feed What is RSS feed?

Quadruple therapy shows 100 percent SVR for HCV patients




Exciting new data presented today at the International Liver CongressTM 2011 show that quadruple treatment in chronic hepatitis C (HCV) patients suppressed the emergence of resistant variants and resulted in a 100% rate of sustained virological response - undetectable HCV RNA - 12 weeks after therapy (SVR12).1.

In the quadruple treatment study, HCV patients were given four drugs in combination; pegylated Interferon-alpha (PegIFN-alpha); ribavirin (RBV); and two different direct-acting antivirals (DAAs) BMS-650032 (an HCV NS3 protease inhibitor) and BMS-790052 (an HCV NS5A replication complex inhibitor).



Quadruple therapy shows 100 percent SVR for HCV patients

The current standard of care (SoC) for HCV treatment is PegIFN-alpha plus RBV � a dual treatment. The addition of DAAs (currently in phase-III clinical trials) marks the next step in therapy evolution � a triple treatment. However, the new data presented today suggests that quadruple treatment could be the next generation of therapy for chronic HCV patients.

Professor Heiner Wedemeyer, EASL'S Secretary General, said: "Quadruple treatment is possibly the future of HCV therapy; this study goes a way to confirming that. While it's expected that the first DAAs and triple treatment will be approved for use later this year, quadruple treatment appears to have a more profound effect on virological response, with less of a resistance problem".

The study may also provide new hope for a growing number of HCV patients who cannot be effectively treated for chronic hepatitis with current therapys.

The Phase-IIa trial looked at a cohort of 21 HCV genotype 1 null responders (patients who have failed to respond to prior therapy), of whom 19 had an unfavourable IL28B genotype, which predisposes HCV patients to therapy failure.

Only about 30% of null responders to PegIFN-alpha/RBV therapy achieve sustained virological response (SVR) when retreated with PegIFN-alpha/RBV plus telaprevir, demonstrating a high unmet medical need.1


Posted by: Mark    Source




Did you know?
Exciting new data presented today at the International Liver CongressTM 2011 show that quadruple treatment in chronic hepatitis C (HCV) patients suppressed the emergence of resistant variants and resulted in a 100% rate of sustained virological response - undetectable HCV RNA - 12 weeks after therapy (SVR12).1.

Medicineworld.org: Quadruple therapy shows 100 percent SVR for HCV patients

SARS Main| SARS Abroad| SARS and Goverment| SARS Information in different languages| Media about SARS| Physicians resources for SARS| Reference information for SARS| Updates on SARS|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.